Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Meta-analysis reveals candidate variants associated with brain traits

Feb. 4, 2022

CIRM grant supports Juvena's preclinical work on JUV-161 for myotonic dystrophy type 1

Feb. 3, 2022

New prolyl endopeptidase inhibitors identified at Accure Therapeutics

Feb. 3, 2022

Sarepta and GenEdit report progress under collaboration for neuromuscular diseases

Feb. 2, 2022

CCR4 mediates postoperative pain through skin dendritic cells

Feb. 2, 2022

ATH-434 demonstrates efficacy in preclinical multiple system atrophy

Jan. 31, 2022

New antipsychotic shows partial agonist activity at DRD2/3 and 5-HT1AR with little 5-HT2AR binding

Jan. 31, 2022

Dual Kv7 channel/TPSO receptor activator GRT-X shows promise in a refractory seizure model

Jan. 31, 2022

Gilgamesh Pharmaceuticals identifies new 5-HT2A receptor agonists

Jan. 28, 2022

Structure-based psychedelic analogue discovery reported

Jan. 28, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...